Osteoprotegerin (OPG): What is Its Potential as a Biomarker or Therapeutic Target?
Osteoprotegerin (OPG): What is Its Potential as a Biomarker or Therapeutic Target?On July 22, 2020, a study published in the journal Cell Death & Differentiation reveals a new regulation mechanism in terms of the osteoprotegerin (OPG). The research implies for the first time that osteoprotegerin (OPG)...
Detailed information

Streptococcus pneumoniae, a Primary Cause of Pneumonia
Streptococcus pneumoniae, a Primary Cause of PneumoniaStreptococcus pneumoniae (S. pneumoniae) is a major cause of pneumonia, meningitis, sepsis and other serious illnesses worldwide. In November 2010, the WHO announced that between 700,000 and 1 million children under the ...
Detailed information

The Multifunctional Enzyme CD38: A Target for Immunotherapeutic Approaches in Cancer
The Multifunctional Enzyme CD38: A Target for Immunotherapeutic Approaches in CancerRecently, CD38 causes fresh concerns in the field of anti-aging because two articles published in Nature Metabolis point that CD38 attributes to the NAD+ consumption [1-2]. NAD support is called by some as the "immortali...
Detailed information

Cervical Cancer, One of the Most Common Killers of Women
Cervical Cancer, One of the Most Common Killers of WomenCancer of the uterine cervix, also called cervical cancer, is among the most preventable human malignancies, yet it remains a leading cause of death among women worldwide [1] [2]. According to the data from World Health ...
Detailed information

An Overview of CD226 and Its Promising Role in Cancer Immunotherapy
An Overview of CD226 and Its Promising Role in Cancer ImmunotherapyNowadays, ample evidence has shown the roles of immune checkpoints in cancer immunotherapy. Intriguingly, CD226, a well-known active receptor, it is increasingly being recognized and researched through the two articles p...
Detailed information

CD73, What a Powerful Therapy Target in Tumor Immune
CD73, What a Powerful Therapy Target in Tumor ImmuneOn October 27, 2020, Akeso, Inc. announced the completion of its first clinical trial in New Zealand for its innovative drug candidate CD73 monoclonal antibody named AK119, which was administered to healthy subjects. AK1...
Detailed information

With the High Potential in Cancer Immunotherapy, CD40 Is Triggering Attention
With the High Potential in Cancer Immunotherapy, CD40 Is Triggering AttentionLast month saw the newest FDA-approved orphan drug APX005M, an anti-CD40 agonist antibody. The company Apexigen announced that FDA has granted orphan drug designation status to APX005M for the treatment esophageal and ga...
Detailed information

CD47, A New Target for Tumor Immune
CD47, A New Target for Tumor ImmuneOn September 4th, 2020, IMAB and AbbVie jointly announced the establishment of a broad global partnership of the innovative CD47 monoclonal antibody lemzoprlimab (TJC4) independently developed by IMAB. IMAB will receive ...
Detailed information

New Mechanism, NRP1 Enhances the Ability of SARS-CoV-2 Infection
New Mechanism, NRP1 Enhances the Ability of SARS-CoV-2 InfectionAn outbreak of SARS-CoV-2 infections has caused a pandemic associated with COVID-19. As the research on the mechanism of the virus invasion is deepening, some potential mechanisms have been revealed. In early February, t...
Detailed information

Hematopoietic Stem Cell Surface Marker
Hematopoietic Stem Cell Surface MarkerHematopoietic stem cells (HSC) are a type of adult stem cells with the characteristics of stem cells: self-renewal and differentiation potential. Hematopoietic stem cells are a kind of pluripotent stem cells derive...
Detailed information

Call icon
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
Address icon
Address
7505 Fannin St Ste 610-322 Houston, TX 77054, USA
Join Us with

Leave a message

check code
© 2007-2023 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1